Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple myeloma. • Costs of peripheral neuropathy in patients treated for multiple myeloma. Download here: Multiple Myeloma Research Review Issue 30Continue Reading

This guide is written for people who have been diagnosed with myeloma. It will also be helpful for their families, friends and health professionals. It provides information about how to live well with myeloma by explaining how to cope with the physical symptoms and side effects and practical implications of living with the disease. Being...Continue Reading

Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM Subclonal TP53 copy number is associated with MM prognosis Download here – Multiple Myeloma Research Review Issue 29Continue Reading

Research Review Multiple Myeloma Summit Highlights include:  High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment Burden of MM in NZ Download hereContinue Reading

Issue 28 of Multiple Myeloma Research Review. Highlights include:  Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to Pri-17-92 inhibition Identification of novel mutational drivers reveals oncogene dependencies in MM Patient reported health-related Q0L from TOURMALINE-MM1 Download hereContinue Reading

Issue 27 of Multiple Myeloma Research Review Highlights include:  Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of heterozygosity indicates homologous repair deficiency in MM. Treatment intensification with SCT + lenalidomide in new MM in CR. Download hereContinue Reading

Issue 26 of Multiple Myeloma Research Review. Highlights include:  Selinexor in relapsed/refractory multiple myeloma HIV antivirals overcome carfilzomib resistance in multiple myeloma Outcome and survival trends in multiple myeloma during 2008-2015 Bortezomib before and after high-dose therapy in multiple myeloma Download hereContinue Reading

ANZMAP Multiple Myeloma Highlights from ASH 2017 This publication provides summaries of key clinically relevant multiple myeloma data presented at the 59th ASH Annual Meeting and Exposition, 9–12 December 2017 in Atlanta, Georgia, USA. The Chair (Associate Professor Peter Mollee) and clinicians involved in the Australian and New Zealand Myeloma Ambassador Program (ANZMAP) selected the...Continue Reading

Issue 25 of Multiple Myeloma Research Review.   Highlights include: Induction VCD. Prediction of outcome in newly diagnosed myeloma Final analysis of survival in the FIRST trial in MM. Daratumumab + VMP for untreated myeloma. Download hereContinue Reading

Issue 24 of Multiple Myeloma Research Review.   Highlights include: Is MRD the best predictor of response? ctDNA and risk of distant relapse. Cardiac safety of bortezomib. Cytogenic evolution in relapsed MM. Download hereContinue Reading